Literature DB >> 27423456

King's Health Questionnaire to assess subjective outcomes after surgical treatment for urinary incontinence: can it be useful?

Rita Luz1,2, Inês Pereira3, Alexandra Henriques3, Ana Luísa Ribeirinho3, Alexandre Valentim-Lourenço3.   

Abstract

INTRODUCTION AND HYPOTHESIS: Midurethral slings (MUS) are the mainstay of treatment for stress urinary incontinence, but the definition of success varies widely amongst studies. The King's Health Questionnaire (KHQ) was designed to evaluate the impact of urinary incontinence on the quality of life. We hypothesised that the KHQ could be useful for postoperative quantitative assessment of subjective outcomes.
MATERIALS AND METHODS: This is a retrospective analysis of 204 patients who underwent incontinence surgery with transobturator MUS between 2004 and 2013. Follow-up was planned at 6, 12 and 24 months and success was evaluated using the cough stress test (objective cure) and the KHQ global score (subjective outcomes). Statistical analysis included receiver operating characteristic (ROC) curves to calculate a cut-off value for the KHQ global score to define subjective cure. The minimal clinically important difference was calculated with a distribution-based method (effect size) to estimate subjective improvement.
RESULTS: Objective cure rates were 97 % and 95 % at 6 and 24 months respectively. ROC curves established the cut-off score at ≤ 31 for subjective cure, with sensitivity of 63-100 % and specificity of 82-88 %. Subjective cure rates were 80 % and 85 % at 6 and 24 months respectively. The minimal clinically important difference was set at 10 and an improvement of ≥ 10 points was defined as subjective improvement. Rates varied between 10 and 13 %.
CONCLUSIONS: This study showed the value of the KHQ as an evaluation tool after UI surgery and determined clinically relevant threshold scores to define subjective outcomes.

Entities:  

Keywords:  Cure; Improvement; Incontinence surgery; King’s Health Questionnaire; Quality of life; Stress urinary incontinence

Mesh:

Year:  2016        PMID: 27423456     DOI: 10.1007/s00192-016-3089-2

Source DB:  PubMed          Journal:  Int Urogynecol J        ISSN: 0937-3462            Impact factor:   2.894


  30 in total

1.  Surgical treatment for female stress urinary incontinence: what is the gold-standard procedure?

Authors:  Maurizio Serati; Stefano Salvatore; Stefano Uccella; Walter Artibani; Giacomo Novara; Linda Cardozo; PierFrancesco Bolis
Journal:  Int Urogynecol J Pelvic Floor Dysfunct       Date:  2009-06

2.  Objective and subjective cure rates after trans-obturator tape (OBTAPE) treatment of female urinary incontinence.

Authors:  Bruno Deval; Jérome Ferchaux; Richard Berry; Sandro Gambino; Calin Ciofu; Arash Rafii; François Haab
Journal:  Eur Urol       Date:  2005-12-20       Impact factor: 20.096

3.  New surgical technique for treatment of stress urinary incontinence TVT-ABBREVO from development to clinical experience.

Authors:  David Waltregny; Jean de Leval
Journal:  Surg Technol Int       Date:  2012-12

Review 4.  Medium-term and long-term outcomes following placement of midurethral slings for stress urinary incontinence: a systematic review and metaanalysis.

Authors:  Giovanni A Tommaselli; Costantino Di Carlo; Carmen Formisano; Annamaria Fabozzi; Carmine Nappi
Journal:  Int Urogynecol J       Date:  2015-05-20       Impact factor: 2.894

5.  Beyond incontinence: the stigma of other urinary symptoms.

Authors:  Emily A Elstad; Simone P Taubenberger; Elizabeth M Botelho; Sharon L Tennstedt
Journal:  J Adv Nurs       Date:  2010-08-23       Impact factor: 3.187

6.  Discrepancy in patient and physician perception of patient's quality of life related to urinary symptoms.

Authors:  Larissa V Rodríguez; Daniel S Blander; Frederick Dorey; Shlomo Raz; Philippe Zimmern
Journal:  Urology       Date:  2003-07       Impact factor: 2.649

7.  Lifetime risk of stress urinary incontinence or pelvic organ prolapse surgery.

Authors:  Jennifer M Wu; Catherine A Matthews; Mitchell M Conover; Virginia Pate; Michele Jonsson Funk
Journal:  Obstet Gynecol       Date:  2014-06       Impact factor: 7.661

8.  Third-line treatment for overactive bladder: should mirabegron be tried before intravesical botulinum toxin A therapy?

Authors:  Aswini Balachandran; Natasha Curtiss; Maya Basu; Jonathan Duckett
Journal:  Int Urogynecol J       Date:  2014-07-17       Impact factor: 2.894

9.  Seven years of objective and subjective outcomes of transobturator (TVT-O) vaginal tape: why do tapes fail?

Authors:  Stavros Athanasiou; Themos Grigoriadis; Dimitrios Zacharakis; Nikolaos Skampardonis; Dionysia Lourantou; Aris Antsaklis
Journal:  Int Urogynecol J       Date:  2013-07-27       Impact factor: 2.894

10.  Novel surgical technique for the treatment of female stress urinary incontinence: transobturator vaginal tape inside-out.

Authors:  Jean de Leval
Journal:  Eur Urol       Date:  2003-12       Impact factor: 20.096

View more
  3 in total

1.  The Relationship between Anxiety and Depression Levels and General Health Status before and 12 Months after SUI Treatment in Postmenopausal Women from the Lower Silesian Population.

Authors:  Maciej Zalewski; Gabriela Kołodyńska; Felicja Fink-Lwow; Anna Mucha; Waldemar Andrzejewski
Journal:  Int J Environ Res Public Health       Date:  2022-04-24       Impact factor: 4.614

2.  Effectiveness of manual lymphatic drainage vs. perineal massage in secundigravida women with gestational oedema: A randomised clinical trial.

Authors:  Mónica de la Cueva-Reguera; David Rodríguez-Sanz; César Calvo-Lobo; Silvia Fernández-Martínez; Beatriz Martínez-Pascual; Yolanda Robledo-Do-Nascimento; María Blanco-Morales; Carlos Romero-Morales
Journal:  Int Wound J       Date:  2020-06-13       Impact factor: 3.315

3.  Understanding the Impact of Urinary Incontinence in Persons with Dementia: Development of an Interdisciplinary Service Model.

Authors:  Patrick Juliebø-Jones; Elizabeth Coulthard; Elizabeth Mallam; Hilary Archer; Marcus J Drake
Journal:  Adv Urol       Date:  2021-06-19
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.